Myanmar’s Special Position in ASEAN: Compared with Singapore, Thailand and Malaysia

1. Key takeaways

Within ASEAN, the differences in legislative progress of medical device regulation are significant: markets such as Singapore, Malaysia and Thailand have each established written device regulatory frameworks, whereas Myanmar has not yet enacted a dedicated law, and its current rules are assembled from three layers: the technical framework of the AMDD, FDA administrative guidelines, and the catch-all authorisation of Section 3, Sub-section 3, item (d) of the Public Health Law (1972).

GRZAN note: the direct consequence of this difference is that compliance certainty in Myanmar is lower than in ASEAN markets that have completed legislation. Companies can plan their pathway on statutory provisions in Singapore, Malaysia and Thailand, whereas in Myanmar they must follow administrative guidelines and case-by-case practice, and retain strategic flexibility. The comparison can be recorded as: 3 dimensions (legislative progress, classification system, entity requirements), 1 core conclusion, and 1 organising approach. In other words, the difference is not a difference of strictness in every respect, but a difference of the kind of certainty on which planning can rest, and that distinction should shape how much of the company’s long-term commitment is anchored to the current rules.

2. Legal basis

The table below summarises the status of the dedicated law, the authorisation basis, the technical framework, the reference markets and Myanmar’s classification and entity requirements. The rows read as two systems in the same region: one anchored in statute, one anchored in administration, sharing the same technical origin.

3. Expert insights

Insight 1: differences in legislative progress determine differences in the shape of compliance risk. In markets with written law, the risk is whether the documents meet the standard; in Myanmar, the risk is that the rules themselves may change. These are different risk species and they call for different responses: in a written-law market, effort is concentrated on meeting a fixed target, while in Myanmar, effort must additionally be spread across tracking, interpretation and the capacity to adapt when a guideline or practice shifts.

Insight 2: Myanmar’s technical standards share the same origin as those of other ASEAN markets. All follow the AMDD’s A–D classification logic, which makes it convenient for companies to reuse existing determinations and classification conclusions. This is the strongest point of continuity across the region: the technical substance travels well between markets, and only the wrapper, meaning the formats, the submitting entity and the process, must be rebuilt locally.

Insight 3: on entity requirements Myanmar is stricter. A local authorised representative is mandatory for submission, and the activities of foreign manufacturers are restricted (24 categories of products, with wholesale or retail licences required). The practical meaning is that in Myanmar the choice of representative is not a convenience decision but a structural one: the representative stands between the manufacturer and every regulatory interaction, and the manufacturer’s own room for direct action is bounded by the licence categories it can lawfully obtain.

Insight 4: on digitalisation Myanmar is in a catch-up position. The e-Submission system is online and two-factor authentication has been mandatory since 8 June 2026, while the electronic handling of renewals and minor changes is still advancing. The direction is clear even if the coverage is partial: processes are migrating to the portal over time, and companies should expect the electronic footprint of their submissions to grow rather than shrink. Planning on that expectation avoids building paper-era routines that will need to be dismantled later.

Insight 5: companies should organise their work on the principle of unified regional standards plus local format adaptation. Reuse the AMDD system at the technical standard level, and adapt documents and processes to the requirements of the Myanmar FDA at the format and procedure level. This division of labour avoids the two classic errors: rebuilding the technical file for every country, and submitting an undifferentiated regional package that ignores local format expectations.

4. Practical recommendations

• Prepare technical documentation to the AMDD system as a unified base. This facilitates reuse across ASEAN markets and keeps the technical substance portable as each market’s requirements evolve.
• Adapt formats and processes separately for Myanmar. Use the format documents prescribed in the guidelines, so the local wrapper matches local expectations exactly.
• Reserve room in the dossier for upgrading when the dedicated law is enacted. Keep the dossier structure elastic, so a new statutory layer can be added without disassembling the file.
• Meet the local authorised representative requirements strictly. Verify the registration and licence qualifications before appointment, since every subsequent submission depends on them.
• Complete the e-Submission account and 2FA configuration as a priority. Place this ahead of the submission, so access is never the reason a filing date slips.

5. Verification checklist

• □ The difference in legislative progress between Myanmar and the reference markets has been confirmed
• □ Technical documentation has been prepared on a unified AMDD basis
• □ Formats and processes have been adapted separately to Myanmar requirements
• □ Room for upgrading has been reserved against the enactment of the dedicated law
• □ The registration and licence qualifications of the local authorised representative have been verified
• □ The account and 2FA configuration has been completed
• □ The items have been incorporated into the registration ledger

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com